We are live on ! Find out more
KDNY

Chinook Therapeutics, Inc. Common Stock
KDNY

Delisted

KDNY was delisted on the 10th of August, 2023.

Back to rankings

2 hedge funds and large institutions have $0 invested in Chinook Therapeutics, Inc. Common Stock in 2023 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 181 closing their positions.

New
Increased
Maintained
Reduced
Closed

99% less funds holding

Funds holding: 185 → 2 (-183)

100% less funds holding in top 10

Funds holding in top 10: 10 → 0 (-10)

100% less capital invested

Capital invested by funds: $2.24B → $0 (-$2.24B)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 181

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
2
Holders Change
-183
Holders Change %
-98.92%
% of All Funds
0.03%
Holding in Top 10
–
Holding in Top 10 Change
-10
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
1
Closed
181
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
SB
Samsara BioCapital
California
-$198M
2
FLSM
Frazier Life Sciences Management
California
-$167M
3
BlackRock
BlackRock
New York
-$164M
4
Vanguard Group
Vanguard Group
Pennsylvania
-$113M
5
State Street
State Street
Massachusetts
-$112M
Name Holding Trade Value Shares
Change 		Change in
Stake
Deutsche Bank
51
Deutsche Bank
Germany
– -$9.18M -238,918 Closed
Bank of New York Mellon
52
Bank of New York Mellon
New York
– -$8.36M -217,625 Closed
Rafferty Asset Management
53
Rafferty Asset Management
New York
– -$8M -208,207 Closed
Two Sigma Advisers
54
Two Sigma Advisers
New York
– -$7.18M -186,880 Closed
HF
55
HRT Financial
New York
– -$6.69M -174,189 Closed
LP
56
LMR Partners
United Kingdom
– -$6.32M -164,578 Closed
Susquehanna International Group
57
Susquehanna International Group
Pennsylvania
– -$6M -156,194 Closed
GF
58
Gabelli Funds
New York
– -$5.95M -154,861 Closed
Man Group
59
Man Group
United Kingdom
– -$5.19M -135,000 Closed
Adage Capital Partners
60
Adage Capital Partners
Massachusetts
– -$5.15M -134,110 Closed
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
61
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Ontario, Canada
– -$5.11M -133,000 Closed
GCIA
62
Gabelli & Co Investment Advisers
New York
– -$4.94M -128,600 Closed
PMAM
63
Picton Mahoney Asset Management
Ontario, Canada
– -$4.8M -125,000 Closed
Jane Street
64
Jane Street
New York
– -$4.47M -116,221 Closed
NFGH
65
Nan Fung Group Holdings
Hong Kong
– -$4.38M -113,950 Closed
AA
66
AQR Arbitrage
Connecticut
– -$4.36M -113,518 Closed
HCM
67
Highbridge Capital Management
New York
– -$4.23M -110,000 Closed
Barclays
68
Barclays
United Kingdom
– -$4.21M -109,656 Closed
DCM
69
Driehaus Capital Management
Illinois
– -$4.11M -107,053 Closed
Citigroup
70
Citigroup
New York
– -$4.02M -104,573 Closed
Point72 Asset Management
71
Point72 Asset Management
Connecticut
– -$3.93M -102,399 Closed
Swiss National Bank
72
Swiss National Bank
Switzerland
– -$3.85M -100,300 Closed
RhumbLine Advisers
73
RhumbLine Advisers
Massachusetts
– -$3.43M -89,242 Closed
Two Sigma Investments
74
Two Sigma Investments
New York
– -$3.41M -88,706 Closed
Citadel Advisors
75
Citadel Advisors
Florida
– -$3.32M -86,464 Closed
1 2
3
4 5

KDNY Hedge Fund Activity: Q3 2023 in Review

2 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Chinook Therapeutics, Inc. Common Stock (KDNY) for Q3 2023, worth a combined $0 — down 100% from $2.24B a quarter earlier.

Sellers outnumbered buyers: 181 funds closed out of KDNY and 0 opened new positions — a net loss of 181 holders — while 1 trimmed existing stakes and 0 added.

The largest seller was Samsara BioCapital, exiting entirely with an estimated $198M sold.

  • 2 institutional investors held Chinook Therapeutics, Inc. Common Stock (KDNY) as of Q3 2023, down from 185 in Q2 2023.
  • Funds reported $0 of Chinook Therapeutics, Inc. Common Stock stock for Q3 2023, down 100% quarter-over-quarter.
  • 0 funds opened new Chinook Therapeutics, Inc. Common Stock positions in Q3 2023 and 181 closed out, a net change of -181 holders.
  • The largest Chinook Therapeutics, Inc. Common Stock seller in Q3 2023 was Samsara BioCapital, an estimated $198M sold.

Based on aggregated 13F filings for Q3 2023.